The 12th meeting of the 11th board of directors and the 11th meeting of the 10th board of supervisors held to review and approve the annual work report and other relevant proposals
Release time:
2023-04-21
General Manager's report pointed out that in 2022, my country's macroeconomic policy will adhere to the general tone of seeking progress while maintaining stability. The annual GDP was 121.02 trillion billion yuan, an increase of 3.0 percent over last year (data source: National Bureau of Statistics). Centering on the general policy of "reform, breakthrough, innovation and development", the company strives to maintain the orderly development of various production and operation work, achieving operating income of 3.56 billion yuan for the whole year, a decrease of 6.43 percent over the same period last year, and net profit attributable to shareholders of 0.288 billion yuan, a decrease of 68.86 percent over the same period last year. By the end of 2022, the company's total assets were 7.321 billion billion yuan, up 4.22 percent year-on-year, and the net assets attributable to shareholders of listed companies were 5.186 billion billion yuan, down 0.41 percent year-on-year.
2022
, the company's industrial chain extension war made new progress. The company set up Yunnan Jianfeng New Building Materials Co., Ltd. to promote its aggregate, machine sand and other projects in an orderly manner, and Yunnan Jianfeng invested 0.133 billion yuan to increase the capital of its subsidiary Jianfeng Exhibition, making it a holding enterprise of the company, and the company's cement business sector has been further developed.
Facing the unfavorable external environment, the company's cement companies continue to implement benchmarking and refined management, steadily implement various technical reforms, strictly control production costs, strive to overcome the pressure of declining demand, and actively expand the sales market. Daye Peak has improved the overall production capacity of the kiln system through technical transformation and operation process optimization of grate cooler, packaging machine and kiln cylinder, combined with the use of MES system for optimal parameter traceability. Actively develop new agents, open up new markets, strengthen cooperation with large enterprises, undertake key projects, effectively cope with the overall weak cement market and maintain the balance of production and sales; vigorously promote the construction of green mines and green factories, and successfully entered the list of national green factories in 2022. Yunnan Jianfeng has strengthened the technological transformation of energy saving and consumption reduction, reformed the kiln head sealing device, grate cooler and other equipment, and improved the kiln output. The dust collector at the bottom of the cement blending warehouse has been added, and the feeding device of the roller press has been reformed, effectively improving the production site environment. Actively implement the brand strategy, adhere to the "direct sales + agent" dual-track sales model, while effectively reducing the sales cost while maintaining the advantages of multi-channel sales. Huang Ping Jianfeng actively studied, explored and applied advanced technology to tackle key problems. Through the transformation of the cone under the decomposition furnace to reduce negative pressure fluctuation, replace the high-temperature feed lock valve, and increase the snowman pushing device of the grate cooler, the stability of the equipment has been improved. Facing the unfavorable demand situation, it actively undertakes key projects externally and strengthens the business skills training of the marketing team internally, with Kaili and Huang Ping as the core markets, maintain the leading sales of the same type of kiln line in the region.2022
, the company's pharmaceutical sector technical reform and engineering construction continued to advance, innovation and research and development to make new progress. Jianfeng Pharmaceutical's annual production of 2 billion tablets of solid preparations (international project) has completed the completion acceptance of construction projects, equipment installation and debugging, certified product registration batch production, completed the human bioequivalence test, submitted registration materials, and entered the waiting stage of cGMP application for certification; jinxi Production Base has completed the completion and acceptance of the technical transformation project of bulk drugs, completed the installation and debugging of the newly added RTO incineration treatment facilities, completed the automatic transformation of the packaging equipment of freeze-dried powder injection and solid preparation production line, and completed the transformation of the refrigeration system of the raw material workshop and the comprehensive preparation building. The construction of the single-dose eye drop production line of Jianfeng Pharmaceutical has also been basically completed and has entered the stage of product stability inspection. The 205 and 206 workshops of Anhui Xinbeika Phase II Project have been completed and put into trial production. The chlorine dioxide workshop has completed the information control transformation and improved the safety guarantee level. The technical renovation project of Moxi Xiaohuan and pharmaceutical intermediates in Jianfeng Beika 102 Workshop has been completed and put into trial operation. The 203, 205 and 206 workshops have been completed and have entered the stage of production plan review. Jianfeng Pharmaceutical and its subsidiaries further increased investment in research and development, continued to promote the phase I clinical trials of the new anti-tumor drug DPT and JFAN-1001 project, and completed the application for production registration of several products such as fluprost eye drops, single-dose sodium hyaluronate eye drops, and mycophenolate mofetil capsules. At present, 11 drugs (including consistency evaluation) have been submitted to the State Drug Administration for production registration.
On the same day, the company also held the 11th meeting of the 10th Board of Supervisors, and reviewed and approved 5 related reports and proposals including the 2022 Board of Supervisors Report of the company. (residual fruit)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page